Publications

 

 

In order to help patients and physicians gain a greater understanding of vitiligo, the following resources are available:


Recommended Reading
Books
Handbook of Vitiligo: Basic Science and Clinical Management
By: Iltefat H Hamzavi (Editor), Bassel H Mahmoud (Editor), Prescilia N Isedeh (Editor)
Hardcover: 202 pages
Publisher: JP Medical Publishers, 2016
Language: English
ISBN-10: 1907816968

ISBN-13: 978-1907816963

 

Vitiligo 2010 Edition
By: Mauro Picardo (Editor), Alain Taïeb (Editor)
Hardcover: 483 pages
Publisher: Springer; 2010 edition (January 29, 2010)
Language: English
ISBN-10: 3540693602
ISBN-13: 978-3540693604
 

Articles
 

General

Vitligo

http://www.ncbi.nlm.nih.gov/pubmed/25596811

 

Vitiligo is Not a Cosmetic Disease

http://www.ncbi.nlm.nih.gov/pubmed/26475548

VitilVitiligo is not a cosmetic disease.go is not a cosmetic disea

Therapy
Afamelanotide and Narrowband UV-B Phototherapy for the Treatment of Vitiligo
http://www.ncbi.nlm.nih.gov/pubmed/25230094

Antioxidants and narrow band-UVB in the treatment of vitiligo: a double-blind placebo controlled trial.
http://www.ncbi.nlm.nih.gov/pubmed/17953631

Oral dexamethasone pulse treatment for vitiligo.
http://www.ncbi.nlm.nih.gov/pubmed/11312430

Autoimmunity
Comorbid autoimmune diseases in patients with vitiligo: A cross-sectional study.
http://www.ncbi.nlm.nih.gov/pubmed/26518171

The prevalence of thyroid disease in patients with vitiligo: a systematic review.
http://www.ncbi.nlm.nih.gov/pubmed/22860695

Autoimmune thyroid disease in vitiligo: multivariate analysis indicates intricate pathomechanisms.
http://www.ncbi.nlm.nih.gov/pubmed/23253044

Pathogenesis

Increased Expression of CXCR3 and its Ligands in Vitiligo Patients and CXCL10 as a Potential Clinical Marker for Vitiligo.
http://www.ncbi.nlm.nih.gov/pubmed/26801009

Mutant HSP70 reverses autoimmune depigmentation in vitiligo.
http://www.ncbi.nlm.nih.gov/pubmed/23447019

Cellular stress and innate inflammation in organ-specific autoimmunity: lessons learned from vitiligo.
http://www.ncbi.nlm.nih.gov/pubmed/26683142

CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo.
http://www.ncbi.nlm.nih.gov/pubmed/24523323

Variant of TYR and autoimmunity susceptibility loci in generalized vitiligo.
http://www.ncbi.nlm.nih.gov/pubmed/20410501

Evaluation
Confetti-like depigmentation: A potential sign of rapidly progressing vitiligo.
http://www.ncbi.nlm.nih.gov/pubmed/26054430

An objective method for the assessment of vitiligo treatment.
http://www.ncbi.nlm.nih.gov/pubmed/18353149

Development and validation of a vitiligo-specific quality-of-life instrument (VitiQoL).
http://www.ncbi.nlm.nih.gov/pubmed/22365883

Surgery
Melanocyte-keratinocyte transplantation procedure in the treatment of vitiligo: the experience of an academic medical center in the United States.
http://www.ncbi.nlm.nih.gov/pubmed/21864935

Research
Guidelines for designing and reporting clinical trials in vitiligo.
http://www.ncbi.nlm.nih.gov/pubmed/21844427

Developing core outcome set for vitiligo clinical trials: international e-Delphi consensus.
http://www.ncbi.nlm.nih.gov/pubmed/25645179